Overview

* Harvard Bioscience Q2 2025 revenue in line with analyst expectations, per LSEG data

* Adjusted EPS for Q2 meets analyst estimates, indicating stable performance

* Company signs credit amendment, extending refinance deadline to Dec 5, 2025

Outlook

* Harvard Bioscience expects Q3 2025 revenue between $19 mln and $21 mln

* Company anticipates Q3 2025 gross margin of 56% to 58%

* Harvard Bioscience ( HBIO ) sees improved operations and strong financial discipline

* Company aims for revenue growth and margin expansion in 2026

Result Drivers

* CASH FLOW IMPROVEMENT - Cash provided by operations improved to $2.8 mln from a negative $0.8 mln in Q2 2024

* CREDIT AMENDMENT - New credit amendment signed, extending refinance deadline to December 5, 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Meet $20.45 $20.40

Revenue mln mln (2

Analysts

)

Q2 Meet -$0.01 -$0.01

Adjusted (2

EPS Analysts

)

Q2 EPS -$0.05

Q2 Net -$2.28

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Harvard Bioscience Inc ( HBIO ) is $3.00, about 82.4% above its August 8 closing price of $0.53

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)